Universität zu Köln

Cramer, Paula, Eichhorst, Barbara, Reinhardt, Hans Christian and Hallek, Michael (2016). Current strategies to create tailored and risk-adapted therapies for CLL patients. Best Pract. Res. Clin. Haematol., 29 (1). S. 111 - 122. OXFORD: ELSEVIER SCI LTD. ISSN 1532-1924

Full text not available from this repository.

Abstract

Given the current dynamics in the development of novel agents for CLL therapy, the task to find optimal, non-toxic combinations has become the primary goal. This article gives an update of the most interesting novel drugs. The strategy of the German CLL Study Group to use these agents in combinations is described in detail, highlighting the strategy and first results of a recently started series of phase II combination trials, the BXX series using agents such as bendamustine, idelalisib, ibrutinib, obinutuzumab, ofatumumab and venetoclax. (C) 2016 Published by Elsevier Ltd.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Cramer, Paula UNSPECIFIED UNSPECIFIED UNSPECIFIED Eichhorst, Barbara UNSPECIFIED UNSPECIFIED UNSPECIFIED Reinhardt, Hans Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-281851
DOI:	10.1016/j.beha.2016.08.010
Journal or Publication Title:	Best Pract. Res. Clin. Haematol.
Volume:	29
Number:	1
Page Range:	S. 111 - 122
Date:	2016
Publisher:	ELSEVIER SCI LTD
Place of Publication:	OXFORD
ISSN:	1532-1924
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CHRONIC LYMPHOCYTIC-LEUKEMIA; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; PREVIOUSLY UNTREATED PATIENTS; STEM-CELL TRANSPLANTATION; LOW-DOSE FLUDARABINE; PHASE-II TRIAL; GENOMIC ABERRATIONS; FRONTLINE TREATMENT; THERAPEUTIC TARGET; 1ST-LINE THERAPY Multiple languages Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/28185